公开(公告)号：US20250064732A1

公开(公告)日：2025-02-27

申请号：US18825795

申请日：2024-09-05

Applicant: PFIZER INC.

Inventor： James Joseph HUSSEY ,  Andrew Gilbert Bright

IPC: A61K9/08 ,  A61K9/00 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US12233135B2

公开(公告)日：2025-02-25

申请号：US17047011

申请日：2019-04-10

Applicant: PRECISION MOLECULAR INC.

Inventor： Christopher Ullman ,  Christine Anne Carrington

IPC: A61K48/00 ,  A61K9/19 ,  A61K38/17 ,  A61K38/20 ,  A61K38/45 ,  A61K39/00 ,  A61K39/395 ,  A61K47/59 ,  A61P35/00

Abstract: The present disclosure provides nucleic acid constructs for the treatment of cancer, comprising a cancer-specific promoter and one or more therapeutic genes.

公开(公告)号：USRE50301E1

公开(公告)日：2025-02-18

申请号：US17894447

申请日：2022-08-24

Applicant: MAPI PHARMA LTD.

Inventor： Ehud Marom ,  Shai Rubnov

IPC: C07K14/00 ,  A61K9/00 ,  A61K9/16 ,  A61K9/19 ,  A61K9/50 ,  A61K38/02

Abstract: Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.

公开(公告)号：US20250041443A1

公开(公告)日：2025-02-06

申请号：US18798342

申请日：2024-08-08

Applicant: ethris GmbH

Inventor： Christian Dohmen ,  Christian Plank ,  Carsten Rudolph ,  Christian Koch

IPC: A61K48/00 ,  A61K9/19 ,  A61K31/713 ,  A61K47/26 ,  A61K47/58 ,  A61K47/59 ,  C08F8/32 ,  C08G73/02 ,  C12N15/87

Abstract: The present invention relates to oligomers, polymers and lipidoids comprising characteristic oligo(alkylene amine) moieties which are useful as vehicles for transfecting a cell with RNA. The present invention furthermore relates to a composition comprising at least a nucleic acid and an oligomer or polymer or a lipidoid comprising such oligo(alkylene amine) moieties and to a method of transfecting a cell using said composition. Furthermore, the present invention relates to pharmaceutical compositions and uses.

公开(公告)号：US20250041424A1

公开(公告)日：2025-02-06

申请号：US18922371

申请日：2024-10-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Willow Diluzio ,  Nobel T. Truong ,  Csanad M. Varga ,  Vaithianathan Palaniappan ,  Jason Brown ,  Catherine Scholz ,  Irving H. Fox

IPC: A61K47/26 ,  A61K9/00 ,  A61K9/19 ,  A61K39/00 ,  A61K39/395 ,  A61K47/18 ,  C07K16/28

Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

公开(公告)号：US20250032417A1

公开(公告)日：2025-01-30

申请号：US18775374

申请日：2024-07-17

Applicant: Hyloris Developments SA

Inventor： Atul Patil

IPC: A61K9/19 ,  A61K31/517 ,  A61K47/10 ,  A61K47/26

Abstract: The invention relates to a novel metolazone lyophilizate composition and a pharmaceutically acceptable diluent that can be used to reconstitute the metolazone lyophilizate for parenteral administration. The invention also relates to a novel metolazone pre-lyophilizate composition as well as uses of the reconstituted metolazone lyophilizate.

公开(公告)号：US12208166B2

公开(公告)日：2025-01-28

申请号：US18383389

申请日：2023-10-24

Applicant: Iterion Therapeutics, Inc.

Inventor： Gowri Sukumar ,  Drazen Ostovic

IPC: A61K9/19 ,  A61K9/16 ,  A61K31/4545

Abstract: Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.

公开(公告)号：US12194051B2

公开(公告)日：2025-01-14

申请号：US17288164

申请日：2019-10-22

Applicant: MERCK PATENT GMBH

Inventor： Anne-Laure Blayo ,  Baptiste Manteau ,  Camille Amalric ,  Stanislas Mayer ,  Stephan Schann ,  Mickaël Fer

IPC: A61K31/553 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5386 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00 ,  A61K9/00 ,  A61K9/02 ,  A61K9/06 ,  A61K9/08 ,  A61K9/19 ,  A61K9/20 ,  A61K9/28 ,  A61K45/06 ,  A61K47/06 ,  A61P31/00

Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

公开(公告)号：US20250013059A1

公开(公告)日：2025-01-09

申请号：US18896693

申请日：2024-09-25

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Akira Tanaka ,  Yasuhiro Kanishima ,  Kenichi Doniwa ,  Hiroaki Komaki ,  Hiroki Kumagai ,  Takashi Sudo ,  Nobuhide Okabayashi

IPC: G02B27/01 ,  A61K9/19 ,  A61K39/00 ,  A61K39/12 ,  B65B3/00 ,  C12N7/00 ,  G02B27/00 ,  G06F1/16 ,  G06F3/01 ,  G06F3/0346 ,  G06V20/20

Abstract: According to one embodiment, a system includes a wearable device configured to be attached to a display configured to display a display image. The wearable device features an optical component set featuring a lens, a first user operable member configured to set an adjustment value relating to a projection angle of the visual image, and a second user operable member configured to set an adjustment value relating to at least one of a color tone or a brightness of the visual image. A position of the visual image is changed by adjusting the projection angle of the visual image using the first user operable member so that the visual image is displayed at a position based on at least one of a shape or a size of the head of the user. The color tone or the brightness of the visual image is changed using the second user operable member.

公开(公告)号：US20250009648A1

公开(公告)日：2025-01-09

申请号：US18709915

申请日：2022-11-16

Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Inventor： Atta Behfar ,  Matthew T. Houdek

IPC: A61K9/00 ,  A61K9/19

Abstract: A composition includes a purified exosome product (PEP) and a pharmaceutically acceptable carrier that includes a supportive matrix. The supportive matrix can include a collagen scaffold, a tissue sealant, or a fibrin sealant. A method of repairing damaged tendon tissue generally includes applying a composition that includes PEP and a pharmaceutically acceptable carrier to damaged tendon tissue. In one or more embodiments, the composition applied to the damaged tendon tissue includes a supportive matrix.